Traumatic Brain Injury - Pipeline Review, H1 2014

News provided by

May 28, 2014, 12:11 ET

LONDON, May 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Traumatic Brain Injury - Pipeline Review, H1 2014

http://www.reportbuyer.com/pharma_healthcare/research_r_d/pipeline/traumatic_brain_injury_1.html

Summary

Global Markets Direct's, 'Traumatic Brain Injury - Pipeline Review, H1 2014', provides an overview of the Traumatic Brain Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Traumatic Brain Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Traumatic Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Traumatic Brain Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Introduction 9
Global Markets Direct Report Coverage 9
Traumatic Brain Injury Overview 10
Therapeutics Development 11
Pipeline Products for Traumatic Brain Injury - Overview 11
Pipeline Products for Traumatic Brain Injury - Comparative Analysis 12
Traumatic Brain Injury - Therapeutics under Development by Companies 13
Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes 18
Traumatic Brain Injury - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Traumatic Brain Injury - Products under Development by Companies 23
Traumatic Brain Injury - Products under Investigation by Universities/Institutes 27
Traumatic Brain Injury - Companies Involved in Therapeutics Development 28
Athersys, Inc. 28
Euroscreen S.A. 29
Acorda Therapeutics, Inc. 30
Oxygen Biotherapeutics, Inc. 31
Neuralstem, Inc. 32
Lixte Biotechnology Holdings, Inc. 33
Lpath, Inc. 34
Neuren Pharmaceuticals Limited 35
RegeneRx Biopharmaceuticals, Inc. 36
NeoStem, Inc. 37
Phylogica Limited 38
NeuroVive Pharmaceutical AB 39
D-Pharm Ltd. 40
SynZyme Technologies, LLC 41
ALSP, Inc. 42
Remedy Pharmaceuticals, Inc. 43
PsychoGenics, Inc. 44
Grupo Ferrer Internacional, S.A. 45
Adamas Pharmaceuticals, Inc. 46
QR Pharma, Inc. 47
NeuroNascent, Inc. 48
vasopharm GmbH 49
Concert Pharmaceuticals, Inc. 50
Intellect Neurosciences, Inc. 51
Omeros Corporation 52
MAPREG 53
M's Science Corporation 54
Encore Therapeutics Inc. 55
NeuroHealing Pharmaceuticals Inc. 56
MandalMed, Inc. 57
BHR Pharma, LLC 58
Cognosci, Inc. 59
STATegics, Inc. 60
Amarantus Bioscience Holdings, Inc. 61
Mnemosyne Pharmaceuticals, Inc. 62
Allinky Biopharma 63
Io Therapeutics, Inc. 64
Sage Therapeutics 65
Tetra Discovery Partners LLC 66
Prevacus, Inc. 67
Bionature E.A. Ltd. 68
Voltarra Pharmaceuticals, Inc. 69
Traumatic Brain Injury - Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Target 72
Assessment by Mechanism of Action 78
Assessment by Route of Administration 84
Assessment by Molecule Type 87
Drug Profiles 90
epoetin alfa - Drug Profile 90
progesterone - Drug Profile 91
progesterone - Drug Profile 92
NeuroSTAT - Drug Profile 93
Oxycyte - Drug Profile 94
VAS-203 - Drug Profile 96
NH-001 - Drug Profile 98
NNZ-2566 - Drug Profile 100
atorvastatin calcium - Drug Profile 102
NeuroSTAT - Drug Profile 103
glyburide - Drug Profile 104
Allopregnanolone - Drug Profile 107
VOLT-02 - Drug Profile 108
SB-623 - Drug Profile 109
RGS-2064 - Drug Profile 110
DP-b99 - Drug Profile 111
amantadine hydrochloride - Drug Profile 114
Drug for Traumatic Brain Injury - Drug Profile 115
MAP-4343 - Drug Profile 116
Posiphen - Drug Profile 117
MultiStem - Drug Profile 119
Lpathomab - Drug Profile 122
RGN-352 - Drug Profile 123
cutamesine - Drug Profile 125
INN-01 - Drug Profile 127
NSI-189 - Drug Profile 128
COG-1410 - Drug Profile 129
AMR-001 - Drug Profile 131
NSI-566 - Drug Profile 133
LB-201 - Drug Profile 135
LB-205 - Drug Profile 136
AC-105 - Drug Profile 137
AMRS-001 - Drug Profile 138
IRX-4204 - Drug Profile 139
ND-478 - Drug Profile 141
STS-E-15 - Drug Profile 142
EPO-Variant - Drug Profile 144
PGI-02776 - Drug Profile 145
Small Molecules to Activate P2Y Receptor for Stroke and Traumatic Brain Injury - Drug Profile 146
Peptides to Inhibit MHC Class I and II for CNS Disorders - Drug Profile 147
PRV-001 - Drug Profile 148
VitalHeme - Drug Profile 149
BHR-310 - Drug Profile 151
felbamate - Drug Profile 152
2-DG - Drug Profile 153
tiplasinin - Drug Profile 155
TLR-4 Antagonists for CNS Disorders - Drug Profile 156
NNZ-2256 - Drug Profile 157
(melatonin + dexamethasone acetate) - Drug Profile 158
CNB-001 - Drug Profile 159
Spirosteroids - Drug Profile 161
Small Molecules Inhibiting BACE-1 for Alzheimer's Disease and Traumatic Brain Injury - Drug Profile 162
Small Molecule to Activate Voltage-Gated Sodium Channe for Central Nervous System Disorders - Drug Profile 163
PYC-35 - Drug Profile 164
PYC-36 - Drug Profile 165
PYC-38 - Drug Profile 166
PYC-98 - Drug Profile 167
Small Molecule for Traumatic Brain Injury and Alzheimer's Disease - Drug Profile 168
Cell Therapy for Spinal Cord and Traumatic Brain Injury - Drug Profile 169
NNI-370 - Drug Profile 171
C-10068 - Drug Profile 172
ESN-502 - Drug Profile 174
AIK-3 - Drug Profile 175
NR-2A Modulators - Drug Profile 176
GPR17 Antagonists for Multiple Nervous System Disorders - Drug Profile 177
HBN-1-TBI - Drug Profile 178
FIB-117 - Drug Profile 179
ALP-496 - Drug Profile 180
Small Molecule to Inhibit PDE4 for Traumatic Brain Injury - Drug Profile 181
R-503 - Drug Profile 182
Traumatic Brain Injury Program - Drug Profile 184
Small Molecules to Inhibit PBR for Central Nervous System Disorders - Drug Profile 185
Traumatic Brain Injury - Recent Pipeline Updates 186
Traumatic Brain Injury - Dormant Projects 233
Traumatic Brain Injury - Discontinued Products 236
Traumatic Brain Injury - Product Development Milestones 237
Featured News & Press Releases 237
Appendix 244
Methodology 244
Coverage 244
Secondary Research 244
Primary Research 244
Expert Panel Validation 244
Contact Us 245
Disclaimer 245

List of Tables

Number of Products under Development for Traumatic Brain Injury, H1 2014 16
Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H1 2014 17
Number of Products under Development by Companies, H1 2014 19
Number of Products under Development by Companies, H1 2014 (Contd..1) 20
Number of Products under Development by Companies, H1 2014 (Contd..2) 21
Number of Products under Development by Companies, H1 2014 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2014 24
Comparative Analysis by Late Stage Development, H1 2014 25
Comparative Analysis by Clinical Stage Development, H1 2014 26
Comparative Analysis by Early Stage Development, H1 2014 27
Products under Development by Companies, H1 2014 28
Products under Development by Companies, H1 2014 (Contd..1) 29
Products under Development by Companies, H1 2014 (Contd..2) 30
Products under Development by Companies, H1 2014 (Contd..3) 31
Products under Investigation by Universities/Institutes, H1 2014 32
Traumatic Brain Injury - Pipeline by Athersys, Inc., H1 2014 33
Traumatic Brain Injury - Pipeline by Euroscreen S.A., H1 2014 34
Traumatic Brain Injury - Pipeline by Acorda Therapeutics, Inc., H1 2014 35
Traumatic Brain Injury - Pipeline by Oxygen Biotherapeutics, Inc., H1 2014 36
Traumatic Brain Injury - Pipeline by Neuralstem, Inc., H1 2014 37
Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2014 38
Traumatic Brain Injury - Pipeline by Lpath, Inc., H1 2014 39
Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Limited, H1 2014 40
Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2014 41
Traumatic Brain Injury - Pipeline by NeoStem, Inc., H1 2014 42
Traumatic Brain Injury - Pipeline by Phylogica Limited, H1 2014 43
Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2014 44
Traumatic Brain Injury - Pipeline by D-Pharm Ltd., H1 2014 45
Traumatic Brain Injury - Pipeline by SynZyme Technologies, LLC, H1 2014 46
Traumatic Brain Injury - Pipeline by ALSP, Inc., H1 2014 47
Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals, Inc., H1 2014 48
Traumatic Brain Injury - Pipeline by PsychoGenics, Inc., H1 2014 49
Traumatic Brain Injury - Pipeline by Grupo Ferrer Internacional, S.A., H1 2014 50
Traumatic Brain Injury - Pipeline by Adamas Pharmaceuticals, Inc., H1 2014 51
Traumatic Brain Injury - Pipeline by QR Pharma, Inc., H1 2014 52
Traumatic Brain Injury - Pipeline by NeuroNascent, Inc., H1 2014 53
Traumatic Brain Injury - Pipeline by vasopharm GmbH, H1 2014 54
Traumatic Brain Injury - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 55
Traumatic Brain Injury - Pipeline by Intellect Neurosciences, Inc., H1 2014 56
Traumatic Brain Injury - Pipeline by Omeros Corporation, H1 2014 57
Traumatic Brain Injury - Pipeline by MAPREG, H1 2014 58
Traumatic Brain Injury - Pipeline by M's Science Corporation, H1 2014 59
Traumatic Brain Injury - Pipeline by Encore Therapeutics Inc., H1 2014 60
Traumatic Brain Injury - Pipeline by NeuroHealing Pharmaceuticals Inc., H1 2014 61
Traumatic Brain Injury - Pipeline by MandalMed, Inc., H1 2014 62
Traumatic Brain Injury - Pipeline by BHR Pharma, LLC, H1 2014 63
Traumatic Brain Injury - Pipeline by Cognosci, Inc., H1 2014 64
Traumatic Brain Injury - Pipeline by STATegics, Inc., H1 2014 65
Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2014 66
Traumatic Brain Injury - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2014 67
Traumatic Brain Injury - Pipeline by Allinky Biopharma, H1 2014 68
Traumatic Brain Injury - Pipeline by Io Therapeutics, Inc., H1 2014 69
Traumatic Brain Injury - Pipeline by Sage Therapeutics, H1 2014 70
Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H1 2014 71
Traumatic Brain Injury - Pipeline by Prevacus, Inc., H1 2014 72
Traumatic Brain Injury - Pipeline by Bionature E.A. Ltd., H1 2014 73
Traumatic Brain Injury - Pipeline by Voltarra Pharmaceuticals, Inc., H1 2014 74
Assessment by Monotherapy Products, H1 2014 75
Assessment by Combination Products, H1 2014 76
Number of Products by Stage and Target, H1 2014 79
Number of Products by Stage and Mechanism of Action, H1 2014 85
Number of Products by Stage and Route of Administration, H1 2014 91
Number of Products by Stage and Molecule Type, H1 2014 94
Traumatic Brain Injury Therapeutics - Recent Pipeline Updates, H1 2014 191
Traumatic Brain Injury - Dormant Projects, H1 2014 238
Traumatic Brain Injury - Dormant Projects (Contd..1), H1 2014 239
Traumatic Brain Injury - Dormant Projects (Contd..2), H1 2014 240
Traumatic Brain Injury - Discontinued Products, H1 2014 241

List of Figures

Number of Products under Development for Traumatic Brain Injury, H1 2014 16
Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H1 2014 17
Number of Products under Development by Companies, H1 2014 18
Number of Products under Investigation by Universities/Institutes, H1 2014 23
Comparative Analysis by Late Stage Development, H1 2014 25
Comparative Analysis by Clinical Stage Development, H1 2014 26
Comparative Analysis by Early Stage Products, H1 2014 27
Assessment by Monotherapy Products, H1 2014 75
Number of Products by Top 10 Target, H1 2014 77
Number of Products by Stage and Top 10 Target, H1 2014 78
Number of Products by Top 10 Mechanism of Action, H1 2014 83
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 84
Number of Products by Top 10 Route of Administration, H1 2014 89
Number of Products by Stage and Top 10 Route of Administration, H1 2014 90
Number of Products by Top 10 Molecule Type, H1 2014 92
Number of Products by Stage and Top 10 Molecule Type, H1 2014 93